iSpecimen entered into a Securities Purchase Agreement to issue 488,281 shares of common stock at $5.12 per share. The company issued 85,202 shares and 403,088 pre-funded warrants for aggregate gross proceeds of approximately $2.5 million. Net proceeds are earmarked for working capital, with up to $900,000 allocated specifically for marketing expenses. The company regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share as of May 12, 2026. The 2025 Annual Meeting of Stockholders has been repeatedly adjourned due to a lack of quorum and is now scheduled for May 29, 2026.